To enhance diagnostic efficacy, a multi-autoantibody signature (anti-DLAT/LIAS/FDX1/COPT1) was constructed, which significantly improved discrimination (NSCLC <i>vs</i> NC: AUC = 0.805; NSCLC <i>vs</i> BPN: AUC = 0.751). The gene discussed is SLC31A1; the disease is non-small cell lung carcinoma.